What is Scancell Holdings Cash Flow from Financing?
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Oct. 2023,
Scancell Holdings received€0.04 Mil more from issuing new shares than it paid to buy back shares.
It received€0.00 Mil from issuing more debt.
It paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received€0.00 Mil from paying cash dividends to shareholders.
It received€0.00 Mil on other financial activities.
In all, Scancell Holdingsearned€0.04 Mil on financial activities for the
six
months ended in Oct. 2023.
Scancell Holdings Cash Flow from Financing Historical Data
The historical data trend for Scancell Holdings's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Scancell Holdings's Cash from Financing for the fiscal year that ended in Apr. 2023 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Oct. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings (FRA:SCP) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Scancell Holdings's issuance of stock for the
six
months ended in Oct. 2023 was €0.04 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Scancell Holdings's repurchase of stock for the
six
months ended in Oct. 2023 was €0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Scancell Holdings's net issuance of debt for the
six
months ended in Oct. 2023 was €0.00 Mil.
Scancell Holdings received€0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Scancell Holdings's net issuance of preferred for the
six
months ended in Oct. 2023 was €0.00 Mil.
Scancell Holdings paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Scancell Holdings's cash flow for dividends for the
six
months ended in Oct. 2023 was €0.00 Mil.
Scancell Holdings received€0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Scancell Holdings's other financing for the
six
months ended in Oct. 2023 was €0.00 Mil.
Scancell Holdings received€0.00 Mil on other financial activities.
Scancell Holdings Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of Scancell Holdings's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:SCP has been successfully added to your 